DCM
REGN icon

DGS Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

DGS Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$321K Buy
415
+110
+36% +$84.2K 0.05% 376
2025
Q4 		$235K Buy
+305
New +$207K 0.04% 403
2024
Q4 		– Sell
-429
Closed -$451K – 326
2024
Q3 		$451K Buy
429
+52
+14% +$57.9K 0.12% 167
2024
Q2 		$396K Buy
377
+1
+0.3% +$969 0.11% 169
2024
Q1 		$362K Hold
376
– – 0.1% 179
2023
Q4 		$330K Sell
376
-1
-0.3% -$823 0.13% 151
2023
Q3 		$310K Sell
377
-12
-3% -$9.43K 0.15% 146
2023
Q2 		$280K Sell
389
-16
-4% -$12.3K 0.14% 160
2023
Q1 		$333K Sell
405
-17
-4% -$12.8K 0.19% 130
2022
Q4 		$304K Sell
422
-76
-15% -$56.1K 0.2% 131
2022
Q3 		$343K Buy
498
+4
+0.8% +$2.52K 0.23% 99
2022
Q2 		$292K Buy
494
+71
+17% +$46.2K 0.24% 109
2022
Q1 		$295K Sell
423
-35
-8% -$22.1K 0.18% 118
2021
Q4 		$289K Buy
+458
New +$282K 0.18% 99

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

DGS Capital Management's REGN Position: Q1 2026 in Review

DGS Capital Management increased its Regeneron Pharmaceuticals (REGN) stake by 36% in Q1 2026, buying an estimated $84.2K and bringing the position to 415 shares worth $321K. The position accounts for 0.05% of the portfolio, ranked #376.

DGS Capital Management first reported a position in REGN in Q4 2021 and has held it in 14 quarters since. The position peaked at $451K in Q3 2024. 1,400 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • DGS Capital Management held 415 shares of Regeneron Pharmaceuticals worth $321K as of Q1 2026.
  • DGS Capital Management bought 110 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $84.2K.
  • Regeneron Pharmaceuticals made up 0.05% of DGS Capital Management's portfolio in Q1 2026, its #376 holding.
  • DGS Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2021 and has held it in 14 quarters since.
  • DGS Capital Management's Regeneron Pharmaceuticals position peaked at $451K in Q3 2024.
  • 1,400 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on DGS Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.